FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...

Kournikova, who stays mostly out of the spotlight, has been with singer Enrique Iglesias since 2001. President Trump and Elon ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

The most common side effects include nausea, diarrhea, and decreased appetite. Mounjaro (tirzepatide) is prescribed to help manage blood sugar levels in adults with type 2 diabetes, along with a ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.

Janssen Pharmaceutica, Titusville, NJ. c Lamictal (lamotrigine) package insert. Research Triangle Park, NC; GlaxoSmithKline; 2005 Aug. d Vidon N, Chaussade S, Noel M et al. Metformin in the ...

One study conducted in Thailand compared the effectiveness of PILs to traditional package inserts (PIs) in enhancing patients' medication safety knowledge. The findings revealed that patients who ...